A selective inhibitor of tyrosine kinase that prevents signal transmission of important growth factors, Erlotinib stops tumour growth. It was approved in the EU in 2005 and in 2007 the indication of non-small cell bronchial carcinoma was extended to include the treatment of pancreatic cancer.